Edge Therapeutics, Inc. and PDS Biotechnology Corporation announced that their respective boards of directors have approved a definitive merger agreement.    The merger is expected to create a combined company with a growing pipeline of next generation cancer immunotherapies based on the proprietary, multi-functional Versamune® technology platform, and sufficient cash to fund operations into 2020. “We believe that the proposed merger of PDS Biotechnology and Edge Therapeutics will...